Short-Term Omeprazole Treatment Does Not Influence Biochemical Parameters of Bone Turnover in Children

Kocsis, István; Arató, András; Bodánszky, H; Szönyi, László; Szabó, Antal; Tulassay, Tivadar; Vásárhelyi, Barna

doi:10.1007/s00223-001-2068-9

Cited by 35 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kocsis et al 53 did not find different biochemical parameters of bone turnover in pediatric patients after omeprazole administration, which is in line with our results. On the other hand, a favorable bone response of omeprazole administration was seen in the study of Mizunashi et al, 22 who showed a suppression in bone resorption in adult patients treated with gastric PPIs.…”

supporting

confidence: 83%

No Increased Bone Formation around Alendronate or Omeprazole Loaded Bioactive Bone Cements in a Femoral Defect

Bodde

Kowalski²,

Spauwen

et al. 2008

Tissue Engineering Part A

View full text Add to dashboard Cite

Alendronate and omeprazole have been found to influence bone healing by interfering with osteoclastic activity, resulting in increased bone formation. The biological effect of these conventional drugs, incorporated into bioactive bone cement (G2B1), was investigated in a rabbit model. The 2 materials and a control were inserted in defects created in the femoral condyle of rabbits. Implantation time was 6 and 12 weeks. After retrieval, micro-computed tomography and histomorphometry were performed to quantify bone mineral density (BMD) and bone volume (BV) of the implant-surrounding bone mass and the percentage of bone-to-implant contact. BMD and BV were similar in all groups. The percentage of bone-to-implant contact was significantly lower in the alendronate and omeprazole groups than in controls after 6 weeks of implantation. After 12 weeks, this difference in bone contact disappeared for the omeprazole but not for the alendronate implants, which were almost completely surrounded by a fibrous capsule, associated with a limited inflammatory response. In conclusion, in the current study, alendronate and omeprazole did not result in better bone healing when incorporated into bioactive bone cement than did plain control implants. Moreover, an additional cytotoxicity assay revealed that alendronate evoked a toxic response.

show abstract

supporting

confidence: 83%

No Increased Bone Formation around Alendronate or Omeprazole Loaded Bioactive Bone Cements in a Femoral Defect

Bodde

Kowalski²,

Spauwen

et al. 2008

Tissue Engineering Part A

View full text Add to dashboard Cite

show abstract

“…Omeprazole is a weak inhibitor of proton transport within osteoclasts [ 18 ]. Although a biochemical study in children did not demonstrate increased bone turnover with shortterm omeprazole use [ 19 ], a comparable study in adults found lower rates of urinary calcium and hydroxyproline excretion with omeprazole compared with H 2 RA use [ 20 ]. The authors hypothesized that omeprazole may suppress osteoclast activity, thereby decreasing bone resorption and possibly having a role in the management of metabolic bone diseases.…”

Section: Calcium Malabsorption and Bone Metabolismmentioning

confidence: 95%

Potential adverse effects of proton pump inhibitors

Coté¹,

Howden

2008

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Proton pump inhibitors (PPIs) have revolutionized the management of gastroesophageal reflux disease and peptic ulcer disease over the past two decades. Among the most commonly prescribed agents worldwide, PPIs' overall safety profile is unquestionable. However, emerging evidence indicates that PPI therapy, particularly with long-term and/or high-dose administration, is associated with several potential adverse effects, including enteric infections (eg, Clostridium difficile), community-acquired pneumonia, and hip fracture, all of which have received much attention recently. We review the current data on these and other potential consequences of PPI therapy. More judicious use of PPIs (eg, administering them in no more than the minimum effective dose to older adult patients) may help to further limit the impact of some of these possible adverse effects.

show abstract

“…Furthermore, the effects of PPIs on skeletal metabolism have not been well studied and the studies available give differing results. In some studies markers of bone turnover have been altered by PPI treatment in humans suggesting PPIs alter bone resorption, whereas in other studies no affect on bone turnover was seen [48,49,66,67]. …”

Section: Long-term Use Of Ppis and Effects On Calcium Absorption/mentioning

confidence: 99%

Association of Long-Term Proton Pump Inhibitor Therapy with Bone Fractures and Effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium

Ito

Jensen

2010

Curr Gastroenterol Rep

271

211

View full text Add to dashboard Cite

Proton pump inhibitors (PPI) are now one of the most widely used classes of drugs. PPIs have proven to have a very favorable safety profile and it is unusual for a patient to stop these drugs because of side effects. However, increasing numbers of patients are chronically taking PPIs for gastroesophageal reflux disease and a number of other common persistent conditions, therefore the long-term potential adverse effects are receiving increasing attention. One area that is receiving much attention and generally has been poorly studied, is the long-term effects of chronic acid suppression on the absorption of vitamins and nutrients. This area has received increased attention because of the reported potential adverse effect of chronic PPI treatment leading to an increased occurrence of bone fractures. This has led to an increased examination of the effects of PPIs on calcium absorption/metabolism as well as numerous cohort, case control and prospective studies of their ability to affect bone density and cause bone fractures. In this article these studies are systematically examined, as well as the studies of the effects of chronic PPI usage on VB12, iron and magnesium absorption. In general the studies in each of thee areas have led to differing conclusions, but when examined systematically, a number of the studies are showing consistent results that support the conclusion that long-term adverse effects on these processes can have important clinical implications.

show abstract

Short-Term Omeprazole Treatment Does Not Influence Biochemical Parameters of Bone Turnover in Children

Cited by 35 publications

References 0 publications

No Increased Bone Formation around Alendronate or Omeprazole Loaded Bioactive Bone Cements in a Femoral Defect

No Increased Bone Formation around Alendronate or Omeprazole Loaded Bioactive Bone Cements in a Femoral Defect

Potential adverse effects of proton pump inhibitors

Association of Long-Term Proton Pump Inhibitor Therapy with Bone Fractures and Effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium

Contact Info

Product

Resources

About